Vicarious Surgical (RBOT) Cash & Equivalents (2020 - 2025)

Vicarious Surgical (RBOT) has reported Cash & Equivalents for 6 consecutive years, with $7.8 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 80.49% year-over-year to $7.8 million in Q4 2025; TTM through Dec 2025 was $7.8 million, a 80.49% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 80.49% from the prior year.
• Cash & Equivalents was $7.8 million for Q4 2025 at Vicarious Surgical, down from $13.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $185.0 million in Q3 2021 and troughed at $1.0 million in Q1 2021.
• A 5-year average of $72.7 million and a median of $57.5 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 15173.98% in 2022 and tumbled 80.49% in 2025, its largest moves.
• Over 5 years, Cash & Equivalents stood at $173.5 million in 2021, then sank by 33.02% to $116.2 million in 2022, then tumbled by 33.87% to $76.8 million in 2023, then plunged by 47.86% to $40.1 million in 2024, then plunged by 80.49% to $7.8 million in 2025.
• The last three Cash & Equivalents figures came in at $7.8 million (Q4 2025), $13.4 million (Q3 2025), and $24.0 million (Q2 2025), per Business Quant data.